Abstract Library

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4148 S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multicentre phase 2 trial

Introduction: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumors (NETS) and the efficacy of existing treatments is sub-optimal.

Conference:

Presenting Author:

Authors: Chi Y, Song L, Liu W, Zhou Y, Miao Y,

Keywords: S-1, temozolomide, thalidomide, neuroendocrine tumor,

#3645 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic neuroendocrine carcinomas (NEC) – A multicenter, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced NECs. Most NECs are hyper vascular, and the efficacy of paclitaxel-based combination regimens in the treatment of multiple digestive cancers has been reported.

Conference:

Presenting Author:

Authors: Zhang P, Li S, Li J, Lin S, Ming L,

Keywords: NEC, nab-paclitaxel, bevacizumab,

#3511 Predictive factors of adverse events onset in GEP-NET patients treated with LRT

Introduction: Since metastatic GEP-NET are low-growing neoplasms, characterised by stability followed by progression, multiple lines of treatment have to be adopted to control distant localisations and symptoms. In this scenario, there are no precise models to assess the occurrence of adverse events during LRT (Ligand Radiotherapy).

Conference:

Presenting Author: Scalorbi F

Authors: Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V,

Keywords: lrt, toxicity, logistic regression, predictive model, gep-net,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,